These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 4712657)

  • 1. Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.
    Sadée W; Dagcioglu M; Schröder R
    J Pharmacol Exp Ther; 1973 Jun; 185(3):686-95. PubMed ID: 4712657
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of spironolactone and canrenone on the digoxin radioimmunoassay.
    Huffman DH
    Res Commun Chem Pathol Pharmacol; 1974 Dec; 9(4):787-90. PubMed ID: 4477402
    [No Abstract]   [Full Text] [Related]  

  • 3. Re-evaluation of the antimineralocorticoid effect of the spironolactone metabolite, canrenone, from plasma concentrations determined by a new high-pressure liquid-chromatographic method.
    Dahlöf CG; Lundborg P; Persson BA; Regårdh CG
    Drug Metab Dispos; 1979; 7(2):103-7. PubMed ID: 38071
    [No Abstract]   [Full Text] [Related]  

  • 4. Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure.
    Sadée W; Schröder R; von Leitner E; Dagcioglu M
    Eur J Clin Pharmacol; 1974; 7(3):195-200. PubMed ID: 4853286
    [No Abstract]   [Full Text] [Related]  

  • 5. Spirolactones: clinical and pharmacologic studies.
    Corvol P; Claire M; Rafestin-Oblin ME; Michaud A; Roth-Meyer C; Menard J
    Adv Nephrol Necker Hosp; 1977; 7():199-215. PubMed ID: 208407
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria.
    Cheng SC; Suzuki K; Sadee W; Harding BW
    Endocrinology; 1976 Oct; 99(4):1097-106. PubMed ID: 976190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spironolactone and canrenoate-K: relative potency at steady state.
    Ramsay L; Asbury M; Shelton J; Harrison I
    Clin Pharmacol Ther; 1977 May; 21(5):602-9. PubMed ID: 858213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion of spironolactone to canrenone and disposition kinetics of spironolactone and canrenoate-potassium in rats.
    Sadée W; Abshagen U; Finn C; Rietbrock N
    Naunyn Schmiedebergs Arch Pharmacol; 1974; 283(3):303-18. PubMed ID: 4276758
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.
    Dasgupta A; Tso G; Wells A
    Ther Drug Monit; 2008 Dec; 30(6):744-7. PubMed ID: 18824952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common metabolite canrenone.
    DeFrance A; Armbruster D; Petty D; Cooper KC; Dasgupta A
    Ther Drug Monit; 2011 Feb; 33(1):128-31. PubMed ID: 21079546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of spironolactone after a single dose: evaluation of the true canrenone serum concentrations during 24 hours.
    Merkus FW; Overdiek JW; Cilissen J; Zuidema J
    Clin Exp Hypertens A; 1983; 5(2):239-48. PubMed ID: 6831747
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of aldosterone antagonists on organ cultures of human prostatic tissue.
    Castro JE; Sellwood RA
    J Pathol; 1974 Aug; 113(4):217-22. PubMed ID: 4139252
    [No Abstract]   [Full Text] [Related]  

  • 13. Spironolactone and potassium canrenoate in normal man.
    Ramsay L; Shelton J; Harrison I; Tidd M; Asbury M
    Clin Pharmacol Ther; 1976 Aug; 20(2):167-77. PubMed ID: 780038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy.
    Andriulli A; Arrigoni A; Gindro T; Karbowiak I; Buzzetti G; Armanini D
    Digestion; 1989; 44(3):155-62. PubMed ID: 2697627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression by the spironolactone metabolite canrenone of plasma testosterone in man.
    Erbler HC
    Naunyn Schmiedebergs Arch Pharmacol; 1974; 285(4):403-6. PubMed ID: 4280523
    [No Abstract]   [Full Text] [Related]  

  • 16. Proceedings: Acute and chronic effects of the aldosterone antagonist spironolactone and its main metabolite canrenone on plasma aldosterone concentration, plasma renin activity, serum electrolytes and on the excretion of aldosterone, fluid and electrolytes in rats.
    Erbler HC; Hilfenhaus M
    Naunyn Schmiedebergs Arch Pharmacol; 1975; 287 Suppl():R52. PubMed ID: 1143449
    [No Abstract]   [Full Text] [Related]  

  • 17. Plasma digoxin radioimmunoassay in patients treated with potassium canrenoate and spironolactone. A comparison of two commerical kits.
    Cristodorescu R; Gavrilescu S; Deutsch G; Berger E
    Agressologie; 1978; 19(6):409-14. PubMed ID: 751526
    [No Abstract]   [Full Text] [Related]  

  • 18. Antagonism of aldosterone in normal subjects by Ro 12-2503 and spironolactone.
    Dux S; Rosenfeld J; Cocco G; Chu D; Gasser DF
    Arzneimittelforschung; 1982; 32(2):164-9. PubMed ID: 7199923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Canrenoate potassium in the treatment of hyperosmolar syndromes during resuscitation].
    Gasperi A; Domenichini E; Ruozi P; Bobbio-Pallavicini F
    Minerva Anestesiol; 1974 Sep; 40(9):448-54. PubMed ID: 4423734
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of oral spironolactone and intravenous canrenoate-K on the digoxin radioimmunoassay.
    Lichey J; Schröder R; Rietbrock N
    Int J Clin Pharmacol Biopharm; 1977 Dec; 15(12):557-9. PubMed ID: 598949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.